Sign-in for customized ASCO content related to your areas of interest.
Explore ACE
Most Viewed
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Dana E. Rathkopf, MD
Date: Jan 25, 2024
Abstract
2024 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
First Author: Peter Robert Galle
Date: Jun 4, 2024
Poster
2023 ASCO GU Cancers Symposium
Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC).
First Author: Toni K. Choueiri
Date: Feb 18, 2023
Journal
JCO Oncology Practice
Results From the ASCO 2019 Survey of Oncology Practice Operations
First Author: Brian Bourbeau
Publish Date: May 12, 2020